The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US, EU4 and UK — built for market access due diligence.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk for due diligence.
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
- Licensing and BD&L assessments
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Core principle:
If this decision is challenged later, what independent reimbursement benchmark was relied upon?
Rating Products
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Capital Risk Insights
Mid-Cap Biotechs Join Trump’s Medicaid Pricing Deals: What Does It Mean for Market Access?
Summary The Trump administration extended its Medicaid low-price model on September 1, 2026, adding mid-cap biotechs to a program previously
Lilly’s $2.9 Billion Merida Buyout: What Does It Mean for Market Access?
Summary Eli Lilly agreed to acquire Merida Biosciences for $2.9 billion, announced August 31, 2026. Merida’s lead drug, MER511, targets
How Cost and Perception Could Reshape the GLP-1 Market: What Does It Mean for Market Access?
Summary Eli Lilly and Novo Nordisk compete with FDA-approved GLP-1 drugs for weight loss — injectables and pills — but
What the 340B Rebate Pilot Means for Market Access Risk
On July 31, 2026, the Health Resources and Services Administration published a revised Notice Regarding the 340B Rebate Model Pilot
Argenx Acquires Forte Biosciences for $2.2 Billion: What Does It Mean for Market Access?
Summary Argenx has agreed to buy Forte Biosciences for up to $2.2 billion. The all-cash offer is $77 per share,
Trump’s Generic Drug Tariffs: What Do They Mean for Market Access?
Summary The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited